U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H20N3O14P3
Molecular Weight 511.2095
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MBC-11

SMILES

CC(O)(P(O)(O)=O)P(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=CC(N)=NC2=O

InChI

InChIKey=HUIKCRXUQCSUJS-ZLRZYOKSSA-N
InChI=1S/C11H20N3O14P3/c1-11(18,29(19,20)21)30(22,23)28-31(24,25)26-4-5-7(15)8(16)9(27-5)14-3-2-6(12)13-10(14)17/h2-3,5,7-9,15-16,18H,4H2,1H3,(H,22,23)(H,24,25)(H2,12,13,17)(H2,19,20,21)/t5-,7-,8+,9-,11?/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H20N3O14P3
Molecular Weight 511.2095
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 4 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:32:09 GMT 2023
Edited
by admin
on Sat Dec 16 11:32:09 GMT 2023
Record UNII
4M53T688S5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MBC-11
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-(5-O-(1,3,4,5,5-PENTAHYDROXY-4-METHYL-1,3,5-TRIOXIDO-2-OXA-1,3,5-TRIPHOSPHAPENT-1-YL)-.BETA.-D-ARABINOFURANOSYL)-
Systematic Name English
4-AMINO-1-(5-O-(1,3,4,5,5-PENTAHYDROXY-4-METHYL-1,3,5-TRIOXIDO-2-OXA-1,3,5-TRIPHOSPHAPENT-1-YL)-.BETA.-D-ARABINOFURANOSYL)-2(1H)-PYRIMIDINONE
Systematic Name English
(1-((((2R,3S,4S,5R)-5-(4-AMINO-2-OXO-PYRIMIDIN-1-YL)-3,4-DIHYDROXY-TETRAHYDROFURAN-2-YL)METHOXY-HYDROXY-PHOSPHORYL)OXY-HYDROXY-PHOSPHORYL)-1-HYDROXY-ETHYL)PHOSPHONIC ACID
Systematic Name English
Code System Code Type Description
CAS
332863-86-2
Created by admin on Sat Dec 16 11:32:09 GMT 2023 , Edited by admin on Sat Dec 16 11:32:09 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
MBC-11
Created by admin on Sat Dec 16 11:32:09 GMT 2023 , Edited by admin on Sat Dec 16 11:32:09 GMT 2023
PRIMARY Official Title: A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD); Purpose: This study evaluates MBC-11 (a conjugate of a bone-targeting vehicle (etidronate) and a cytostatic agent (ara-C) in patients with malignant tumors with CIBD. This is a first use in human.
PUBCHEM
44463769
Created by admin on Sat Dec 16 11:32:09 GMT 2023 , Edited by admin on Sat Dec 16 11:32:09 GMT 2023
PRIMARY
FDA UNII
4M53T688S5
Created by admin on Sat Dec 16 11:32:09 GMT 2023 , Edited by admin on Sat Dec 16 11:32:09 GMT 2023
PRIMARY
NCI_THESAURUS
C125901
Created by admin on Sat Dec 16 11:32:09 GMT 2023 , Edited by admin on Sat Dec 16 11:32:09 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Class: Anti-hypercalcaemic, Anti-neoplastic, Arabino-nucleoside, Bisphosphonate, Calcium regulator, Drug conjugate, Pyrimidine nucleoside, Small molecule; Mechanism of Action: Bone resorption factor inhibitor, DNA synthesis inhibitor; Highest Development Phase: Phase I for Bone metastases; Most Recent Events: 01 Dec 2015 Osteros Biomedica completes a phase I trial in Bone metastases in Russia (IV) (NCT02673060), 27 Oct 2014 Phase-I clinical trials in Bone metastases in Russia (IV) (NCT02673060), 19 Sep 2012 MBC 11, the lead candidate from MBC Pharma's cancer therapeutics research programme, licensed to Osteros Biomedica worldwide